Novartis

COMBI-APlus | CDRB436F2410

NCT03551626

JCP051

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Status:

Closed to Accrual

26459-200.png

IIIb

Phase

Line of Therapy.png

Adjuvant

Line of Therapy

Disease Stage.png

Prevention

Disease Stage

Target.png

Biomarker(s)

BRAF V600

Investigational

Product

Bruton's tyrosine kinase (Btk) inhibitor

Treatment Arms

o Experimental: Dabrafenib and trametinib combination therapy